Among the handful of peptides marketed for anxiety and cognitive support, selank is one of the most mechanistically interesting. It is a seven-amino-acid synthetic analog of a short fragment of the human immunoglobulin peptide tuftsin, developed by the Russian Academy of Sciences in collaboration with the Institute of Molecular Genetics. In Russia, it is a registered pharmaceutical with an anxiolytic indication. In the West, it has no regulatory status and the research literature is almost entirely in Russian — a familiar pattern for peptide neuropsychopharmacology originating in the Soviet and post-Soviet research traditions.
Key Takeaways
- Seven amino acids: Thr-Lys-Pro-Arg-Pro-Gly-Pro (Thr-Lys-Pro-Arg + Pro-Gly-Pro). The first four residues are the tuftsin fragment; the Pro-Gly-Pro tail stabilises the molecule against enzymatic degradation.
- Developed by Russian Academy of Sciences in the 1980s–1990s. Registered in Russia as an anxiolytic.
- Non-sedating, non-dependence-forming anxiolytic. The core marketing and research claim is anxiety reduction without sedation or benzodiazepine-class side effects.
- Primary mechanism: BDNF upregulation, serotonin and GABA system modulation, and effects on enkephalin degradation.
- Intranasal administration is the typical delivery route in Russian clinical use. Oral bioavailability is poor.
- Not approved by FDA or EMA. No Western Phase 3 program exists. Clinical literature is almost entirely Russian-language.
Mechanism of Action
Selank's effects appear to operate through several parallel pathways:
- BDNF (brain-derived neurotrophic factor) upregulation. Multiple animal studies have shown that selank administration elevates hippocampal BDNF. BDNF is central to synaptic plasticity, learning, and mood regulation; chronic stress and depression consistently reduce it.
- GABA system modulation. Selank interacts with GABAergic signalling without acting as a direct GABA-A receptor agonist. The anxiolytic effect occurs without the sedation, cognitive impairment, or dependence profile of benzodiazepines.
- Serotonin and dopamine effects. Receptor binding and neurotransmitter release studies show modulation of monoamine systems, though the receptor-level specificity is less well characterised than for standard psychiatric drugs.
- Enkephalinase inhibition. Selank slows the degradation of endogenous enkephalins (opioid peptides), extending their signalling. This may underlie some of the mood and anxiety effects.
Preclinical Data
Animal models have consistently shown:
- Anxiolytic effects in standard behavioural assays (elevated plus maze, open field)
- Improved performance in memory and learning tasks
- Protection against stress-induced depressive-like behaviour
- No sedation or motor impairment at anxiolytic doses
- No evidence of tolerance development with repeated dosing
The pattern that distinguishes selank from benzodiazepines in these models is important: equivalent anxiolytic effect size without the cognitive, motor, or dependence liabilities. Whether this translates to humans at scale is a question Western-standard trials have not answered.
Clinical Data
In Russian clinical literature, selank has been studied in:
- Generalized anxiety disorder — reported efficacy comparable to standard anxiolytics in small open-label trials
- Neurasthenia and adjustment disorders — anxiolytic and cognitive-performance improvements
- Anxiety-related comorbidities in psychiatric and neurological populations
Methodological caveats mirror the broader Russian peptide-neuropsychopharmacology literature:
- Small sample sizes
- Open-label or weakly controlled designs
- Non-standardised endpoints
- Limited independent replication
- Publication in regional journals with limited English dissemination
Cognitive Effects
Beyond anxiety, selank is studied as a "nootropic" — an agent that enhances cognitive function in healthy individuals or protects it under stress. The claims typically include:
- Improved attention and working memory under stress
- Reduced fatigue in cognitively demanding tasks
- Faster recovery from mental exhaustion
Supportive data exists at the mechanism level (BDNF, synaptic plasticity) and in small performance studies, but as with the anxiolytic claims, large well-controlled Western-standard trials are absent.
Administration and Pharmacokinetics
Selank is almost always administered intranasally in Russian clinical use. Oral bioavailability is poor — peptides this short are rapidly degraded by gastric acid and digestive enzymes. The intranasal route bypasses first-pass metabolism and provides some direct access to the central nervous system via the olfactory epithelium.
Typical reported dosing in Russian literature is in the microgram range per administration, applied one or more times daily. Half-life after intranasal delivery is short, consistent with the rapid onset and offset profile reported clinically.
Safety Profile
Russian clinical reports consistently describe selank as well-tolerated with no significant adverse events at anxiolytic doses:
- No sedation
- No motor or cognitive impairment
- No dependence or withdrawal reported
- No overdose cases documented in the published literature
As with other peptides in this research tradition, the absence of reported adverse events is not the same as a comprehensive pharmacovigilance database. Long-term exposure data in large populations outside the Russian clinical registration dataset is limited.
Regulatory and Access Status
- Russia: Registered pharmaceutical with an anxiolytic indication
- United States: Not FDA-approved; sold as a "research chemical" through various international suppliers
- European Union: Not approved; no central authorisation
- Other markets: Status varies; often grey-market import
Research-use import to Western countries carries the usual off-label and regulatory considerations.
How Selank Compares to Other Anxiolytics
The theoretical niche selank occupies — if the Russian clinical data holds up at Western-standard rigour — is distinctive:
- vs benzodiazepines: similar anxiolytic effect without sedation, cognitive impairment, tolerance, or dependence
- vs SSRIs: rapid onset (hours, not weeks); but weaker evidence for sustained mood-disorder treatment
- vs buspirone: similar non-sedating profile; different mechanism (BDNF/enkephalin vs serotonin 5-HT1A partial agonism)
Whether this theoretical profile translates into real-world superiority has not been established at Western regulatory standards.
Frequently Asked Questions
Is selank approved by the FDA?
No. Selank is not FDA-approved for any indication. It is registered as a pharmaceutical in Russia but has no Western regulatory status.
Does selank work like a benzodiazepine?
No. Benzodiazepines are direct GABA-A receptor positive allosteric modulators. Selank modulates BDNF, enkephalinase, and GABA signalling indirectly, with a different clinical profile — anxiolytic effect without sedation or dependence.
Is selank addictive?
Russian clinical literature reports no evidence of dependence, tolerance, or withdrawal. Independent long-term Western studies are limited.
How is selank administered?
Almost always intranasally. Oral bioavailability is poor because the peptide is degraded in the digestive tract.
Can selank improve cognitive performance in healthy people?
The nootropic claim rests on BDNF upregulation and small performance studies. The data suggests mechanism-level support but does not meet the standard for cognitive-enhancement claims in healthy individuals under Western regulatory frameworks.
What is the relationship between selank and semax?
Both are short synthetic peptides developed in Russia as neuropsychopharmacology research tools. Semax is based on a fragment of ACTH; selank is based on a fragment of tuftsin. Different peptide families, overlapping research traditions, somewhat different clinical niches (semax leans more cognitive/neuroprotective, selank more anxiolytic).
Primary sources:
- PubMed — Selank research literature
- PubMed — Selank increases BDNF expression in rat hippocampus
- PubMed — Comparative anxiolytic efficacy of selank vs medazepam
Research disclaimer: Selank is not approved by the FDA or EMA. This article is an educational summary of published research for scientific interest only. It does not constitute medical advice.
